[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Profound Medical Corp (PROF)

Profound Medical Corp (PROF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 251,843
  • Shares Outstanding, K 36,341
  • Annual Sales, $ 16,100 K
  • Annual Income, $ -42,570 K
  • EBIT $ -35 M
  • EBITDA $ -35 M
  • 60-Month Beta 0.73
  • Price/Sales 15.76
  • Price/Cash Flow N/A
  • Price/Book 5.09

Options Overview Details

View History
  • Implied Volatility 91.64% (-2.54%)
  • Historical Volatility 56.99%
  • IV Percentile 22%
  • IV Rank 10.61%
  • IV High 445.45% on 02/18/26
  • IV Low 49.65% on 09/04/25
  • Expected Move (DTE 8) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 119
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 3,376
  • Open Int (30-Day) 2,322
  • Expected Range 6.67 to 6.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.23
  • Number of Estimates 2
  • High Estimate $-0.22
  • Low Estimate $-0.23
  • Prior Year $-0.26
  • Growth Rate Est. (year over year) +11.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.63 +0.68%
on 07/24/26
8.50 -21.53%
on 08/04/26
-0.48 (-6.71%)
since 07/13/26
3-Month
6.30 +5.87%
on 06/26/26
8.50 -21.53%
on 08/04/26
-0.43 (-6.06%)
since 05/13/26
52-Week
3.76 +77.39%
on 09/10/25
8.95 -25.47%
on 01/13/26
+1.22 (+22.39%)
since 08/13/25

Most Recent Stories

More News
Profound Medical Launches ‘Let's Huddle’, a Global Community Supporting Men Throughout Their Prostate Care Journey

TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp.  (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...

PRN.TO : 9.36 (-3.70%)
PROF : 6.67 (-3.75%)
Profound Medical Reports Second Quarter 2026 Financial Results

– Operating expenses decline 16%, helping drive a 39% improvement in net loss – – Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing – ...

PRN.TO : 9.36 (-3.70%)
PROF : 6.67 (-3.75%)
Profound Medical's Revenue Guidance Suggests the Payer Coverage Thesis Is Finally Being Put to the Test

Barchart Research What to Expect from PROF Earnings PROF Generated August 5, 2026 Current Price $7.99 EPS Estimate $$-0.22 Consensus Rating Strong Buy Average Move 10.33% Profound Medical's Revenue Guidance...

PROF : 6.67 (-3.75%)
Robotic Radical Prostatectomy Comes Up ‘Short’ in CAPTAIN Trial

TORONTO, July 24, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative...

PRN.TO : 9.36 (-3.70%)
PROF : 6.67 (-3.75%)
Profound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to Follow

TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative...

PRN.TO : 9.36 (-3.70%)
PROF : 6.67 (-3.75%)
Profound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026

TORONTO, July 15, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that its MRI-guided, AI-powered, Robotically-Driven...

PRN.TO : 9.36 (-3.70%)
PROF : 6.67 (-3.75%)
Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) --   Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...

PRN.TO : 9.36 (-3.70%)
PROF : 6.67 (-3.75%)
Profound Medical Annual General and Special Meeting of Shareholders Voting Results

Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - Profound Medical Corp. (TSX: PRN) (NASDAQ: PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General and...

PRN.TO : 9.36 (-3.70%)
PROF : 6.67 (-3.75%)
Profound Medical Q1 Earnings Call Highlights

Profound Medical (NASDAQ:PROF) reported sharply higher first-quarter revenue and reiterated its view that adoption of its TULSA prostate treatment platform is moving toward broader commercial use, supported...

PROF : 6.67 (-3.75%)
Profound Medical Reports Strong First Quarter 2026 Financial Results

– Quarterly results marked by 104% revenue growth and improved operating performance – – Company issues full-year 2026 revenue guidance – – Announces Humana is now covering the TULSA...

PRN.TO : 9.36 (-3.70%)
PROF : 6.67 (-3.75%)

Business Summary

Profound Medical Corp. is a medical technology company. It is focused on a therapeutics platform which provides the precision of real-time Magnetic Resonance Imaging technology for the incision-free ablation of diseased tissue. The company principally commercialized the TULSA-PRO(R) and Sonalleve(R)...

See More

Key Turning Points

3rd Resistance Point 7.47
2nd Resistance Point 7.31
1st Resistance Point 6.99
Last Price 6.67
1st Support Level 6.51
2nd Support Level 6.35
3rd Support Level 6.03

See More

52-Week High 8.95
Fibonacci 61.8% 6.97
Last Price 6.67
Fibonacci 50% 6.36
Fibonacci 38.2% 5.74
52-Week Low 3.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.